Medscape

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children

Clin Drug Invest. 2007;27(8):509-531. Antiretroviral drugs (ARVs) can be divided into four different classes according to their modes of action: nucleoside or nucleotide reverse transcriptase ...
Medscape

Certain HIV Meds Linked to Reduced Alzheimer’s Risk

Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in an analysis of two ...
Monthly Prescribing Reference

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia. HealthDay News — Exposure to nucleoside reverse transcriptase inhibitors ...
Nature

Association between nucleoside and nucleotide reverse transcriptase inhibitor use and primary open-angle glaucoma risk in All of Us

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Verywell Health on MSN

List of approved HIV antiretroviral drugs

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Antiretroviral drugs help prevent HIV from replicating in the body.
clinicaladvisor.com

New option for those starting HIV therapy

Indication: HIV-1 infection in antiretroviral treatment-naïve adult patients, in combination with other antiretroviral agents. Pharmacology: Rilpivirine is a diarylpyrimidine NNRTI of HIV-1 and ...
The American Journal of Managed Care

FDA Approval of DOR/ISL Expands HIV Treatment Options Beyond INSTIs: Amy Colson, MD, MPH

Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety. AJMC: This regimen is the first nonintegrase inhibitor 2-drug combination ...
Business Wire

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...
MPR

Two-Drug, Single-Tablet Idvynso Receives FDA Approval for HIV-1

Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.
clinicaladvisor.com

Intelence- New drug for patients with HIV-1 infection

HIV-1 infection, in combination with other antiretrovirals, intreatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase ...
Nature

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...